Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
Moderna(MRNA) stock is priced at $145.00, giving the company a market capitalization of 58.1B. It carries a P/E multiple of -18.23.
During the trading session on 2026-09-07, Moderna(MRNA) shares reached a daily high of $157.47 and a low of $141.52. At a current price of $145.00, the stock is +2.5% higher than the low and still -7.9% under the high.
Trading activity shows a volume of 14.97M, compared to an average daily volume of 24.29M.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $176.66 and a low of $22.28.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $176.66 and a low of $22.28.
MRNA News
Key Points Moderna has had great success with its mRNA technology used for vaccines. Its promising trial results for a cancer vaccine have many investors exci...
...
Moderna stock has delivered a very large 1 year gain, yet the valuation checks still point to an expensive profile rather than a clear bargain. For investors lo...
Analyst ratings
62%
of 26 ratingsMore MRNA News
Moderna (MRNA -2.23%) has been one of the better-performing large-cap biotechs this year. The company's shares are up 404% to date and have soared 515% over the...
Moderna (NasdaqGS:MRNA) has begun a Phase 3 trial of its mRNA-based bird flu vaccine candidate mRNA-1018 with backing from CEPI, widening its pipeline beyond CO...
Moderna MRNA recently secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine. The decision is a significant milestone for the company, whi...
Moderna (MRNA) stock was down about 3% in Thursday’s pre-market trading after Rothschild Redburn analyst Simon Baker downgraded his rating on the biotechnology...
Rothschild & Co Redburn downgraded Moderna (MRNA) to Sell from Neutral with a price target of $81, up from $40. The firm views the Phase 3 INTerpath-001 trial o...
Shares of Moderna Inc (NASDAQ:MRNA) are trading lower Wednesday morning, taking a breather following a 170% surge over the trailing month. Traders are balancing...
Moderna ( (MRNA) ) just unveiled an update. On September 1, 2026, Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due 2032,...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.